249 related articles for article (PubMed ID: 29084472)
1. How Should Discrete Choice Experiments with Duration Choice Sets Be Presented for the Valuation of Health States?
Mulhern B; Norman R; Shah K; Bansback N; Longworth L; Viney R
Med Decis Making; 2018 Apr; 38(3):306-318. PubMed ID: 29084472
[TBL] [Abstract][Full Text] [Related]
2. Is Dimension Order Important when Valuing Health States Using Discrete Choice Experiments Including Duration?
Mulhern B; Norman R; Lorgelly P; Lancsar E; Ratcliffe J; Brazier J; Viney R
Pharmacoeconomics; 2017 Apr; 35(4):439-451. PubMed ID: 27873226
[TBL] [Abstract][Full Text] [Related]
3. A pilot discrete choice experiment to explore preferences for EQ-5D-5L health states.
Norman R; Cronin P; Viney R
Appl Health Econ Health Policy; 2013 Jun; 11(3):287-98. PubMed ID: 23649892
[TBL] [Abstract][Full Text] [Related]
4. Valuing Health Using Time Trade-Off and Discrete Choice Experiment Methods: Does Dimension Order Impact on Health State Values?
Mulhern B; Shah K; Janssen MF; Longworth L; Ibbotson R
Value Health; 2016; 19(2):210-7. PubMed ID: 27021755
[TBL] [Abstract][Full Text] [Related]
5. Valuing EQ-5D-5L health states 'in context' using a discrete choice experiment.
Cole A; Shah K; Mulhern B; Feng Y; Devlin N
Eur J Health Econ; 2018 May; 19(4):595-605. PubMed ID: 28569351
[TBL] [Abstract][Full Text] [Related]
6. Using Discrete Choice Experiments with Duration to Model EQ-5D-5L Health State Preferences.
Mulhern B; Bansback N; Hole AR; Tsuchiya A
Med Decis Making; 2017 Apr; 37(3):285-297. PubMed ID: 27681988
[TBL] [Abstract][Full Text] [Related]
7. Valuing the AD-5D Dementia Utility Instrument: An Estimation of a General Population Tariff.
Comans TA; Nguyen KH; Ratcliffe J; Rowen D; Mulhern B
Pharmacoeconomics; 2020 Aug; 38(8):871-881. PubMed ID: 32314315
[TBL] [Abstract][Full Text] [Related]
8. Investigating the relative value of health and social care related quality of life using a discrete choice experiment.
Mulhern B; Norman R; De Abreu Lourenco R; Malley J; Street D; Viney R
Soc Sci Med; 2019 Jul; 233():28-37. PubMed ID: 31153085
[TBL] [Abstract][Full Text] [Related]
9. The Use of a Discrete Choice Experiment Including Both Duration and Dead for the Development of an EQ-5D-5L Value Set for Australia.
Norman R; Mulhern B; Lancsar E; Lorgelly P; Ratcliffe J; Street D; Viney R
Pharmacoeconomics; 2023 Apr; 41(4):427-438. PubMed ID: 36720793
[TBL] [Abstract][Full Text] [Related]
10. Preparatory study for the revaluation of the EQ-5D tariff: methodology report.
Mulhern B; Bansback N; Brazier J; Buckingham K; Cairns J; Devlin N; Dolan P; Hole AR; Kavetsos G; Longworth L; Rowen D; Tsuchiya A
Health Technol Assess; 2014 Feb; 18(12):vii-xxvi, 1-191. PubMed ID: 24568945
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan.
Shiroiwa T; Ikeda S; Noto S; Igarashi A; Fukuda T; Saito S; Shimozuma K
Value Health; 2016; 19(5):648-54. PubMed ID: 27565282
[TBL] [Abstract][Full Text] [Related]
12. Testing a discrete choice experiment including duration to value health states for large descriptive systems: addressing design and sampling issues.
Bansback N; Hole AR; Mulhern B; Tsuchiya A
Soc Sci Med; 2014 Aug; 114(100):38-48. PubMed ID: 24908173
[TBL] [Abstract][Full Text] [Related]
13. Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L.
Hobbins A; Barry L; Kelleher D; Shah K; Devlin N; Goni JMR; O'Neill C
Pharmacoeconomics; 2018 Nov; 36(11):1345-1353. PubMed ID: 30051267
[TBL] [Abstract][Full Text] [Related]
14. United States Valuation of EQ-5D-5L Health States Using an International Protocol.
Pickard AS; Law EH; Jiang R; Pullenayegum E; Shaw JW; Xie F; Oppe M; Boye KS; Chapman RH; Gong CL; Balch A; Busschbach JJV
Value Health; 2019 Aug; 22(8):931-941. PubMed ID: 31426935
[TBL] [Abstract][Full Text] [Related]
15. Efficient Designs for Valuation Studies That Use Time Tradeoff (TTO) Tasks to Map Latent Utilities from Discrete Choice Experiments to the Interval Scale: Selection of Health States for TTO Tasks.
Che M; Pullenayegum E
Med Decis Making; 2023 Apr; 43(3):387-396. PubMed ID: 36866604
[TBL] [Abstract][Full Text] [Related]
16. Peruvian Valuation of the EQ-5D-5L: A Direct Comparison of Time Trade-Off and Discrete Choice Experiments.
Augustovski F; Belizán M; Gibbons L; Reyes N; Stolk E; Craig BM; Tejada RA
Value Health; 2020 Jul; 23(7):880-888. PubMed ID: 32762989
[TBL] [Abstract][Full Text] [Related]
17. Implausible States: Prevalence of EQ-5D-5L States in the General Population and Its Effect on Health State Valuation.
Marten O; Mulhern B; Bansback N; Tsuchiya A
Med Decis Making; 2020 Aug; 40(6):735-745. PubMed ID: 32696728
[TBL] [Abstract][Full Text] [Related]
18. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol.
Oppe M; Devlin NJ; van Hout B; Krabbe PF; de Charro F
Value Health; 2014 Jun; 17(4):445-53. PubMed ID: 24969006
[TBL] [Abstract][Full Text] [Related]
19. Dutch Tariff for the Five-Level Version of EQ-5D.
M Versteegh M; M Vermeulen K; M A A Evers S; de Wit GA; Prenger R; A Stolk E
Value Health; 2016 Jun; 19(4):343-52. PubMed ID: 27325326
[TBL] [Abstract][Full Text] [Related]
20. Valuing the SF-6Dv2 Classification System in the United Kingdom Using a Discrete-choice Experiment With Duration.
Mulhern BJ; Bansback N; Norman R; Brazier J;
Med Care; 2020 Jun; 58(6):566-573. PubMed ID: 32221100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
